Human papilloma virus vaccine associated uveitis

Henry D. Holt, David M. Hinkle, Naomi S. Falk, Frederick (Fritz) Fraunfelder, Frederick W. Fraunfelder

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To report a possible association between human papilloma virus (HPV) vaccination and uveitis. Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects, World Health Organization and Food and Drug Administration were collected on uveitis associated with human papilloma virus vaccination. A MEDLINE search was performed using keywords "uveitis," "iritis," "iridocyclitis," "human papilloma virus," "Cervarix", and "Gardasil." Main Outcome Measures: Data garnered from spontaneous reports included the age, gender, adverse drug reaction (ADR), date of administration, concomitant administration of other vaccinations, time until onset of ADR, other systemic reactions, and dechallenge and rechallenge data. Results: A total of 24 case reports of uveitis associated with human papilloma virus vaccination were identified, all cases were female, and the median age was 17. Median time from HPV vaccination to reported ADR was 30 days (range 0-476 days). Discussion: According to World Health Organization criteria, the relationship between human papilloma virus vaccination and uveitis is "possible." Causality assessments are based on the time relationship of drug administration, uveitis development and re-challenge data. Conclusions: Clinicians should be aware of a possible bilateral uveitis and papillitis following HPV vaccination.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalCurrent Drug Safety
Volume9
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Papillomaviridae
Papillomavirus Vaccines
Uveitis
Viruses
Vaccination
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Health
Iritis
Iridocyclitis
Papilledema
United States Food and Drug Administration
MEDLINE
Causality
Registries
Outcome Assessment (Health Care)

Keywords

  • Adverse reaction
  • Human papilloma virus
  • Papilledema
  • Papillitis
  • Retinitis
  • Uveitis
  • Vaccines

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology
  • Pharmacology

Cite this

Human papilloma virus vaccine associated uveitis. / Holt, Henry D.; Hinkle, David M.; Falk, Naomi S.; Fraunfelder, Frederick (Fritz); Fraunfelder, Frederick W.

In: Current Drug Safety, Vol. 9, No. 1, 2014, p. 65-68.

Research output: Contribution to journalArticle

Holt, HD, Hinkle, DM, Falk, NS, Fraunfelder, FF & Fraunfelder, FW 2014, 'Human papilloma virus vaccine associated uveitis', Current Drug Safety, vol. 9, no. 1, pp. 65-68. https://doi.org/10.2174/15748863113086660062
Holt, Henry D. ; Hinkle, David M. ; Falk, Naomi S. ; Fraunfelder, Frederick (Fritz) ; Fraunfelder, Frederick W. / Human papilloma virus vaccine associated uveitis. In: Current Drug Safety. 2014 ; Vol. 9, No. 1. pp. 65-68.
@article{ebc8bd24bc3a4a0aab205c761323cf21,
title = "Human papilloma virus vaccine associated uveitis",
abstract = "Purpose: To report a possible association between human papilloma virus (HPV) vaccination and uveitis. Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects, World Health Organization and Food and Drug Administration were collected on uveitis associated with human papilloma virus vaccination. A MEDLINE search was performed using keywords {"}uveitis,{"} {"}iritis,{"} {"}iridocyclitis,{"} {"}human papilloma virus,{"} {"}Cervarix{"}, and {"}Gardasil.{"} Main Outcome Measures: Data garnered from spontaneous reports included the age, gender, adverse drug reaction (ADR), date of administration, concomitant administration of other vaccinations, time until onset of ADR, other systemic reactions, and dechallenge and rechallenge data. Results: A total of 24 case reports of uveitis associated with human papilloma virus vaccination were identified, all cases were female, and the median age was 17. Median time from HPV vaccination to reported ADR was 30 days (range 0-476 days). Discussion: According to World Health Organization criteria, the relationship between human papilloma virus vaccination and uveitis is {"}possible.{"} Causality assessments are based on the time relationship of drug administration, uveitis development and re-challenge data. Conclusions: Clinicians should be aware of a possible bilateral uveitis and papillitis following HPV vaccination.",
keywords = "Adverse reaction, Human papilloma virus, Papilledema, Papillitis, Retinitis, Uveitis, Vaccines",
author = "Holt, {Henry D.} and Hinkle, {David M.} and Falk, {Naomi S.} and Fraunfelder, {Frederick (Fritz)} and Fraunfelder, {Frederick W.}",
year = "2014",
doi = "10.2174/15748863113086660062",
language = "English (US)",
volume = "9",
pages = "65--68",
journal = "Current Drug Safety",
issn = "1574-8863",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Human papilloma virus vaccine associated uveitis

AU - Holt, Henry D.

AU - Hinkle, David M.

AU - Falk, Naomi S.

AU - Fraunfelder, Frederick (Fritz)

AU - Fraunfelder, Frederick W.

PY - 2014

Y1 - 2014

N2 - Purpose: To report a possible association between human papilloma virus (HPV) vaccination and uveitis. Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects, World Health Organization and Food and Drug Administration were collected on uveitis associated with human papilloma virus vaccination. A MEDLINE search was performed using keywords "uveitis," "iritis," "iridocyclitis," "human papilloma virus," "Cervarix", and "Gardasil." Main Outcome Measures: Data garnered from spontaneous reports included the age, gender, adverse drug reaction (ADR), date of administration, concomitant administration of other vaccinations, time until onset of ADR, other systemic reactions, and dechallenge and rechallenge data. Results: A total of 24 case reports of uveitis associated with human papilloma virus vaccination were identified, all cases were female, and the median age was 17. Median time from HPV vaccination to reported ADR was 30 days (range 0-476 days). Discussion: According to World Health Organization criteria, the relationship between human papilloma virus vaccination and uveitis is "possible." Causality assessments are based on the time relationship of drug administration, uveitis development and re-challenge data. Conclusions: Clinicians should be aware of a possible bilateral uveitis and papillitis following HPV vaccination.

AB - Purpose: To report a possible association between human papilloma virus (HPV) vaccination and uveitis. Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects, World Health Organization and Food and Drug Administration were collected on uveitis associated with human papilloma virus vaccination. A MEDLINE search was performed using keywords "uveitis," "iritis," "iridocyclitis," "human papilloma virus," "Cervarix", and "Gardasil." Main Outcome Measures: Data garnered from spontaneous reports included the age, gender, adverse drug reaction (ADR), date of administration, concomitant administration of other vaccinations, time until onset of ADR, other systemic reactions, and dechallenge and rechallenge data. Results: A total of 24 case reports of uveitis associated with human papilloma virus vaccination were identified, all cases were female, and the median age was 17. Median time from HPV vaccination to reported ADR was 30 days (range 0-476 days). Discussion: According to World Health Organization criteria, the relationship between human papilloma virus vaccination and uveitis is "possible." Causality assessments are based on the time relationship of drug administration, uveitis development and re-challenge data. Conclusions: Clinicians should be aware of a possible bilateral uveitis and papillitis following HPV vaccination.

KW - Adverse reaction

KW - Human papilloma virus

KW - Papilledema

KW - Papillitis

KW - Retinitis

KW - Uveitis

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84895443864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895443864&partnerID=8YFLogxK

U2 - 10.2174/15748863113086660062

DO - 10.2174/15748863113086660062

M3 - Article

VL - 9

SP - 65

EP - 68

JO - Current Drug Safety

JF - Current Drug Safety

SN - 1574-8863

IS - 1

ER -